title: Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing.
abstract: BACKGROUND
  Olopatadine 0.2% is the first topical ophthalmic antihistamine/mast cell stabilizer indicated for once-daily dosing.
  
  
  OBJECTIVE
  This review provides a comprehensive description of the pharmacology of the olopatadine molecule, as well as of the clinical efficacy, tolerability, and safety of olopatadine 0.2% ophthalmic solution.
  
  
  METHODS
  References cited in this review were obtained from the PubMed biomedical literature database. Also included were several posters presented at nationally renowned ophthalmology-related conferences.
  
  
  CONCLUSIONS
  Olopatadine 0.2% was found to be a safe and effective medication for the reduction of itching with a duration of action of up to 24 h. The added convenience of a once-a-day dosing regimen is a major advancement in this drug class.
authors.affiliation: Schepens Eye Research Institute, Boston, Massachusetts, USA. abelson@vision.eri.harvard.edu
authors.forename: Mark B
authors.initials: MB
authors.lastname: Abelson
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Gomes
mesh_terms: D018926:Anti-Allergic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003233:Conjunctivitis, Allergic / Q000188:drug therapy* / Q000503:physiopathology; D003990:Dibenzoxepins / Q000009:adverse effects / Q000627:therapeutic use*; D039563:Histamine H1 Antagonists, Non-Sedating / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D000069605:Olopatadine Hydrochloride; D009883:Ophthalmic Solutions / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D018926:Anti-Allergic Agents; D003990:Dibenzoxepins; D039563:Histamine H1 Antagonists, Non-Sedating; D009883:Ophthalmic Solutions; D000069605:Olopatadine Hydrochloride